Abstract
This report presents original, combined mode of treatment of preinvasive endometrial cancer (IA/G1) in young women with polycystic ovarian syndrome. The objective of the study was the assessment of treatment with natural female sexual hormones in combination with antidiabetic, antioxidative, antidopaminergic, and antiserotonin therapy on the concentrations of hormones and serotonin in blood serum in young women with polycystic ovary syndrome and preinvasive endometrial cancer. This study was performed within 12 months. The study was conducted in the Department of Menopause and Andropause of the Pomeranian Medical University in Szczecin, Poland. PARTICIPANTS AND STUDY DESIGN: Participants were 57 young PCOS women with concomitant preinvasive endometrial cancer (1A/G1). These women were 18–29 years old. They were treated with modified transdermal hormonal replacement therapy. Moreover, in permanent combined treatment, metformax 850 mg/d, bromcriptine mesylate 2.5 mg/d, and melatonin 5 mg/d were applied. Interventions in the study included blood sampling and dilation and curettage. The concentrations of gonadotropins, estrogens (estrone, 17-estradiol), progesterone, total/free T, and prolactin in basic conditions and after a metoclopramide stimulating test, dehydroepiandrosterone sulfate, and serotonin in blood serum were measured. A significant increase in the concentrations of gonadotropins, estrogens, and progesterone was found. Moreover, the concentrations of androgens, prolactin, and serotonin were significantly decreased. Micronized estradiol and progesterone in primary, preinvasive endometrial cancer (IA/G1) in young women, with polycystic ovarian syndrome with concomitant antidiabetic, antioxidative, antidopaminergic, and antiserotonin therapy, favorably influenced on the concentrations of female sexual hormones and lipid metabolism and caused the restoration of normal endometrium.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
